Opinion|Videos|August 12, 2024
Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches
The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What gaps remain in identifying likely non-responders to immunotherapy to guide alternative treatments?
- How does the toxicity profile of immuno-oncology regimens compare to standard chemotherapy options?
- Are there ongoing trials or research on novel combination approaches to overcome resistance and improve immunotherapy efficacy?
Advertisement
Related to this article
Leaders from Boehringer Ingelheim, Incyte, Pfizer, and Takeda told the audience at Patient-Centered Oncology Care® that artificial intelligence (AI) is compressing discovery timelines, but that gaps in testing, data, and community access still decide which patients benefit.
Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.
Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.
Advertisement
Advertisement
Trending on AJMC
1
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
2
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
3
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
4
Occasional Cannabis Use Linked to 40% Higher Odds of Stroke
5